Navigation Links
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
Date:2/11/2009

--Preliminary Data from Ongoing Study Shows Seven of 14 Evaluable Patients Achieved Objective Tumor Response by the End of Two Treatment Cycles--

--Bavituximab Has Now Produced Positive Early Results in All Three Ongoing Phase II Combination Therapy Cancer Trials--

TUSTIN, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that its lead product candidate bavituximab achieved the pre-specified Stage A primary endpoint in an ongoing Phase II clinical trial in patients with advanced breast cancer. The Phase II trial is an open-label, Simon two-stage design to evaluate the safety and efficacy of bavituximab in combination with the chemotherapy drugs carboplatin and paclitaxel in locally advanced or metastatic breast cancer patients. Fourteen of the 15 patients enrolled in Stage A were deemed evaluable for tumor response, with seven patients achieving an objective response by approximately eight weeks, after completing two treatment cycles. Six of the patients achieved partial tumor responses and one patient achieved a complete tumor response, according to RECIST criteria.

With the Stage A pre-specified primary endpoint achieved, the design of the clinical trial allows for an additional 31 study patients to be enrolled.

"We have now achieved early success in all of our ongoing Phase II bavituximab cancer trials, surpassing our pre-specified primary endpoint criteria for the number of patients achieving an objective tumor response in each of the three clinical studies, " said Steven W. King, president and CEO of Peregrine. "The results reported today reinforce the positive early data seen in our Phase II breast cancer trial assessing bavituximab in combination with docetaxel, as well as the promising early data we reported last week from our Pha
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... As the U.S. Supreme Court considers the ... the Affordable Care Act (ACA), an investigation by the ... RAND Corporation and Express Scripts provides an unprecedented look ... enrollees. , The analysis is published online as ... also appear in the journal’s June issue. , The ...
(Date:5/27/2015)... BBB Code of Business Practices represents sound advertising, selling ... confidence in business. The Code is built on the ... elements of creating and maintaining trust in business. This ... Businesses based in the United States and Canada that ... accredited by BBB. , To be accredited by the ...
(Date:5/27/2015)... May 27, 2015 Hundreds of ... behalf of individuals who allegedly suffered gynecomastia (male ... use of the antipsychotic drug continue to move ... in Pennsylvania’s Philadelphia Court of Common Pleas. According ... its bellwether trial program, as the third trial ...
(Date:5/27/2015)... IL (PRWEB) May 27, 2015 While ... treat hair loss, a new pilot study conducted by ... Restoration Surgery (ISHRS) has found hair follicle grafting can ... cutting-edge research was partially funded by ISHRS, which offers ... relating to hair restoration. , In the past ...
(Date:5/27/2015)... Stamford, CT (PRWEB) May 27, 2015 ... Skin Institute based in Stamford, CT has been selected ... of the first physicians nationwide (and the only physician ... injectable which allows for the removal of submental ... little to no recovery time, no surgery and minimal ...
Breaking Medicine News(10 mins):Health News:Large-Scale Analysis of Medication Data Provides Insights into Who Is Covered by Affordable Care Act 2Health News:Large-Scale Analysis of Medication Data Provides Insights into Who Is Covered by Affordable Care Act 3Health News:Large-Scale Analysis of Medication Data Provides Insights into Who Is Covered by Affordable Care Act 4Health News:Carson Energy Receives A+ Accredited Rating For 19 Consecutive Years 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3
... finds , THURSDAY, June 11 (HealthDay News) -- Mad cow ... somehow goes astray and deprives the healthy brain cells of ... considered a prion disease because it has been found to ... is found on the surface of many cells -- including ...
... ... media age. , ... (Vocus) June 11, 2009 -- From cyberbullying and violent video games to social networking and ... To help parents navigate this new and changing landscape, the Center on Media and ...
... of the crime in cancer are guilty of the initiation and ... disease, a team led by scientists at The University of Texas ... Cancer Cell . "We have a smoking gun" that ... that makes them are abnormally expressed in many types of cancer, ...
... Wii may help treat symptoms of Parkinson,s disease, including ... Parkinson,s disease is a degenerative disease that impairs ... game console, which simulates various sports and activities, could ... found additional benefits as well. "The Wii allows ...
... fifth most common malignancy worldwide and the third leading ... been associated with HCC. However, the relationship between type ... the effects of antidiabetic therapy on HCC risk have ... led by Dr. Valter Donadon from Pordenone Hospital addressed ...
... common cancers in China. Although the association between the ... the relation between smoking, alcohol drinking, family history of ... still remains uncertain. So it is important to investigate ... sporadic colorectal cancer. A research team led by ...
Cached Medicine News:Health News:Protein Branded As Culprit in Mad Cow Disease 2Health News:Center on Media and Child Health Launches "Ask the Mediatrician" 2Health News:Center on Media and Child Health Launches "Ask the Mediatrician" 3Health News:Researchers identify 4 new targets for breast cancer 2Health News:Wii-hab may enhance Parkinson's treatment 2
(Date:5/27/2015)... 27, 2015 Research and ... the  "North America Portable X Ray Devices Market ...  report to their offering.       (Logo: ... market for Portable X-Ray Devices is ... 2014 to 2020 X-Ray is a ...
(Date:5/27/2015)... 27, 2015 The global vitreoretinal ... market with analysis and forecast of revenue. This market ... is estimated to grow at a CAGR of 8.9 ... the TOC of the global vitreoretinal surgery devices market ... provided. This report also provides a glimpse of the ...
(Date:5/27/2015)... 2015  Marcio Donatelli, a senior marketing associate with the animal health ... volunteer work in a healthcare setting in Bangkok, Thailand ... for people in need with respect and dignity is the guiding star ... -based Elanco employee in a LillyPad blog . Donatelli ... , Colombia , France , ...
Breaking Medicine Technology:North America Portable X Ray Devices Market Report 2015 - Growth, Trends And Forecasts 2014-2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 3Lilly Sends Employees to Serve in Vulnerable Communities around the World 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 3
... Md., May 16, 2011 Science, public health, and ... Drug Administration. Information in this document is designed for credentialed ... of May 16, 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... any regulatory or enforcement actions due to legal limitations. ...
... RATON, Fla., May 16, 2011 Breckenridge Pharmaceutical, ... have reached an agreement with Takeda Pharmaceutical Company ... litigation related to Pioglitazone Hydrochloride 15 mg, 30 ... version of Actos®. Under the terms of the ...
Cached Medicine Technology:FDA News & Notes - Week of May 16, 2011 2FDA News & Notes - Week of May 16, 2011 3Breckenridge Pharmaceutical Announces Settlement of Actos® (Pioglitazone Hydrochloride) Patent Litigation 2
Proven and Efficient Stand-Alone Device. Offers a choice between alternate breath and every breath delivery. This model provides alternate breath delivery....
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
... An All-In-One Conserver., ,Offers an average 5:1 ... ,Allows the use of a standard cannula. ... and lightweight cylinders offers ambulatory oxygen patients a ... backed by a 2-year warranty. ...
Medicine Products: